Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters
Clinical and Translational Science · 2024-04 · 17 (4)
DOI: 10.1111/cts.13799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 18.04.2024. Verfasst von Yu Liu Ho und 4 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Ritonavir, Cytochrome P-450 CYP3A, Benzamides, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Momelotinib—approved for treatment of myelofibrosis in adults with anemia—and its major active metabolite, M21, were assessed as drug–drug interaction (DDI) victims with a strong cytochrome P450 (CYP) 3A4 inhibitor (multiple‐dose ritonavir), an organic anion transporting polypeptide (OATP) 1B1/1B3 inhibitor (single‐dose rifampin), and a strong CYP3A4 inducer (multiple‐dose rifampin). Momelotinib DDI perpetrator potential (multiple‐dose) was evaluated with CYP3A4 and breast cancer resistance protein (BCRP) substrates (midazolam and rosuvastatin, respectively). DDI was assessed from changes in maximum plasma concentration ( C max ), area under the concentration–time curve (AUC), time to reach C max , and half‐life. The increase in momelotinib (23% C max , 14% AUC) or M21 (30% C max , 24% AUC) exposure with ritonavir coadministration was not clinically relevant. A moderate increase in momelotinib (40% C max , 57% AUC) and minimal change in M21 was observed with single‐dose rifampin. A moderate decrease in momelotinib (29% C max , 46% AUC) and increase in M21 (31% C max , 15% AUC) were observed with multiple‐dose rifampin compared with single‐dose rifampin. Due to potentially counteracting effects of OATP1B1/1B3 inhibition and CYP3A4 induction, multiple‐dose rifampin did not significantly change momelotinib pharmacokinetics compared with momelotinib alone ( C max no change, 15% AUC decrease). Momelotinib did not alter the pharmacokinetics of midazolam (8% C max , 16% AUC decreases) or 1′‐hydroxymidazolam (14% C max , 16% AUC decreases) but increased rosuvastatin C max by 220% and AUC by 170%. Safety findings were mild in this short‐term study in healthy volunteers. This analysis suggests that momelotinib interactions with OATP1B1/1B3 inhibitors and BCRP substrates may warrant monitoring for adverse reactions or dose adjustments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- GSK, Collegeville, Pennsylvania, USA.
ORCID-Profile: Yu Liu Ho, Pete Gorycki, Geraldine Ferron-Brady, Paul Martin, Georgios Vlasakakis
Zitieren
APA
Ho, Y. L., Gorycki, P., Ferron-Brady, G., Martin, P., & Vlasakakis, G. (2024). Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters. Clinical and Translational Science, 17(4). https://doi.org/10.1111/cts.13799
Vancouver
Ho YL, Gorycki P, Ferron-Brady G, Martin P, Vlasakakis G. Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters. Clinical and Translational Science. 2024;17(4). doi:10.1111/cts.13799
BibTeX
@article{Ho2024,
author = {Ho, Yu Liu and Gorycki, Pete and Ferron-Brady, Geraldine and Martin, Paul and Vlasakakis, Georgios},
title = {Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters},
journal = {Clinical and Translational Science},
year = {2024},
volume = {17},
number = {4},
doi = {10.1111/cts.13799}
}
EUVIMED